Loading patent…
AssigneePurdue Research Foundation
InventorsHarm Hogenesch, Juan Francisco Hernandez-Franco
Estimating the term…
A method of prophylactically or therapeutically vaccinating a subject for cancer comprising administering to the subject an immune response-inducing effective amount of a composition comprising (a) an agonist of the stimulator of interferon (IFN) genes (STING) and (b) a tumor (or cancer) antigen or neoantigen, both (a) and (b) of which are adsorbed onto cationic phytoglycogen (PG) nanoparticles; a microneedle device (e.g., microneedle patch) comprising a plurality of microneedles on/in which are contained cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or a neoantigen; a needle-free injector comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen; and a kit comprising (a) a microneedle device or a needle-free injector and (b) a composition comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen.
A method of prophylactically or therapeutically vaccinating a subject for cancer, which method comprises administering to the subject an immune response-inducing effective amount of a composition comprising an agonist of the stimulator of interferon (IFN) genes (STING) and a tumor (or cancer) antigen, both of which are adsorbed onto cationic phytoglycogen (PG) nanoparticles, whereupon the subject is vaccinated for cancer.
A microneedle device comprising a plurality of microneedles onor in which are contained cationic phytoglycogen (PG) nanoparticles onto which are adsorbed (i) an agonist of the stimulator of interferon (IFN) genes (STING) and (ii) a tumor (or cancer) antigen or a neoantigen.
The microneedle device of claim 22, which is a microneedle patch.
A needle-free injector containing a composition comprising cationic phytoglycogen (PG) nanoparticles onto which are adsorbed (i) an agonist of the stimulator of interferon (IFN) genes (STING) and (ii) a tumor (or cancer) antigen or a neoantigen.
A kit comprising a microneedle device and a composition comprising (or consisting essentially of or consisting of) cationic phytoglycogen (PG) nanoparticles onto which are adsorbed (i) an agonist of the stimulator of interferon (IFN) genes (STING) and (ii) a tumor (or cancer) antigen or a neoantigen.
A kit comprising a needle-free injector and a composition comprising cationic phytoglycogen (PG) nanoparticles onto which are adsorbed (i) an agonist of the stimulator of interferon (IFN) genes (STING) and (ii) a tumor (or cancer) antigen or a neoantigen.
A pharmaceutical composition for intradermal immunization against a cancer, the composition comprising a NanoST nanoparticle adjuvant and a cancer antigen adsorbent.
A method of administering a combination immunotherapy, wherein the method comprises:
Dependencies are inferred from the claim text.